company background image
5006

GlaxoSmithKline PharmaceuticalsBSE:500660 Stock Report

Last Price

₹1.74k

Market Cap

₹294.5b

7D

-1.3%

1Y

13.7%

Updated

17 Jan, 2022

Data

Company Financials +
500660 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends3/6

500660 Stock Overview

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally.

GlaxoSmithKline Pharmaceuticals Competitors

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹2.0t

Dr. Reddy's Laboratories

BSE:500124

₹775.5b

Cipla

NSEI:CIPLA

₹734.3b

Torrent Pharmaceuticals

BSE:500420

₹539.4b

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKline Pharmaceuticals
Historical stock prices
Current Share Price₹1,738.15
52 Week High₹1,917.00
52 Week Low₹1,379.00
Beta0.12
1 Month Change-2.75%
3 Month Change18.63%
1 Year Change13.68%
3 Year Change24.26%
5 Year Change27.70%
Change since IPO1,377.71%

Recent News & Updates

Shareholder Returns

500660IN PharmaceuticalsIN Market
7D-1.3%-0.4%1.8%
1Y13.7%12.2%38.6%

Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: 500660 underperformed the Indian Market which returned 36.2% over the past year.

Price Volatility

Is 500660's price volatile compared to industry and market?
500660 volatility
500660 Average Weekly Movement4.8%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.7%
10% most volatile stocks in IN Market9.8%
10% least volatile stocks in IN Market4.1%

Stable Share Price: 500660 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 500660's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19244,283Sridhar Venkateshhttps://india-pharma.gsk.com

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, gastrointestinal, nutrition, dermatology, respiratory, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Betnovate, Calpol, Ceftum, and Synflorix brands.

GlaxoSmithKline Pharmaceuticals Fundamentals Summary

How do GlaxoSmithKline Pharmaceuticals's earnings and revenue compare to its market cap?
500660 fundamental statistics
Market Cap₹294.45b
Earnings (TTM)₹4.96b
Revenue (TTM)₹34.71b

59.3x

P/E Ratio

8.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
500660 income statement (TTM)
Revenue₹34.71b
Cost of Revenue₹14.23b
Gross Profit₹20.48b
Expenses₹15.52b
Earnings₹4.96b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)29.29
Gross Margin59.01%
Net Profit Margin14.30%
Debt/Equity Ratio0%

How did 500660 perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

102%

Payout Ratio

Valuation

Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

59.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500660 (₹1738.15) is trading above our estimate of fair value (₹469.29)

Significantly Below Fair Value: 500660 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500660 is poor value based on its PE Ratio (59.3x) compared to the Indian Pharmaceuticals industry average (26x).

PE vs Market: 500660 is poor value based on its PE Ratio (59.3x) compared to the Indian market (23.5x).


Price to Earnings Growth Ratio

PEG Ratio: 500660 is poor value based on its PEG Ratio (4.1x)


Price to Book Ratio

PB vs Industry: 500660 is overvalued based on its PB Ratio (22.7x) compared to the IN Pharmaceuticals industry average (3.3x).


Future Growth

How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

14.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 500660's forecast earnings growth (14.5% per year) is above the savings rate (6.7%).

Earnings vs Market: 500660's earnings (14.5% per year) are forecast to grow slower than the Indian market (20.6% per year).

High Growth Earnings: 500660's earnings are forecast to grow, but not significantly.

Revenue vs Market: 500660's revenue (8.4% per year) is forecast to grow slower than the Indian market (12.7% per year).

High Growth Revenue: 500660's revenue (8.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (34.1%)


Past Performance

How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?

-6.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500660 has high quality earnings.

Growing Profit Margin: 500660 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 500660's earnings have declined by 6.5% per year over the past 5 years.

Accelerating Growth: 500660 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 500660 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (29.7%).


Return on Equity

High ROE: 500660's Return on Equity (38.3%) is considered high.


Financial Health

How is GlaxoSmithKline Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 500660's short term assets (₹21.8B) exceed its short term liabilities (₹14.8B).

Long Term Liabilities: 500660's short term assets (₹21.8B) exceed its long term liabilities (₹2.8B).


Debt to Equity History and Analysis

Debt Level: 500660 is debt free.

Reducing Debt: 500660 has no debt compared to 5 years ago when its debt to equity ratio was 0.09%.

Debt Coverage: 500660 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500660 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.73%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 500660's dividend (1.73%) is higher than the bottom 25% of dividend payers in the Indian market (0.3%).

High Dividend: 500660's dividend (1.73%) is in the top 25% of dividend payers in the Indian market (1.34%)


Stability and Growth of Payments

Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500660's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (102.5%), 500660's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 500660's dividends in 3 years are not forecast to be well covered by earnings (117.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Sridhar Venkatesh

1.75yrs

Tenure

₹82,146,000

Compensation

Mr. Sridhar Venkatesh serves as Managing Director and Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkl...


CEO Compensation Analysis

Compensation vs Market: Sridhar's total compensation ($USD1.11M) is above average for companies of similar size in the Indian market ($USD571.56K).

Compensation vs Earnings: Insufficient data to compare Sridhar's compensation with company performance.


Leadership Team

Experienced Management: 500660's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: 500660's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GlaxoSmithKline Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Pharmaceuticals Limited
  • Ticker: 500660
  • Exchange: BSE
  • Founded: 1924
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹294.453b
  • Shares outstanding: 169.41m
  • Website: https://india-pharma.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Pharmaceuticals Limited
  • GSK House
  • Dr. Annie Besant Road
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/17 16:16
End of Day Share Price2022/01/17 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.